Compare iShares MSCI Australia ETF (EWA) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Australia ETF vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? iShares MSCI Australia ETF trades at $28.55 (market cap $1.19B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.61 (market cap $977.37M). The key difference: iShares MSCI Australia ETF is the larger of the two by market cap, and iShares MSCI Australia ETF is more actively traded (5,792,656 versus 2,742,564). Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Australia ETF for 61 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| EWA | MRVI | |
|---|---|---|
Market Cap | $1.19B | $977.37M |
Volume | 5,792,656 | 2,742,564 |
Sector | Broad Market / Factor | Health |
52-Week High | $30.43 | $9.00 |
52-Week Low | $24.95 | $2.83 |
Typical Hold Time | 61 Days | 0 Days |
Enterprise Value | — | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWA, the iShares MSCI Australia ETF, trades at $28.77 with a modest 0.35% daily gain. Technical indicators show a bearish bias with moving averages signaling caution, though oscillators remain neutral. Recent news highlights institutional activity with Squarepoint Ops reducing its stake by 91.2% while Empowered Funds and Cetera Investment Advisers increased positions. Australian market sentiment is challenged by inflation concerns and oil price volatility affecting the commodity-driven economy.
The ETF faces headwinds from Australian economic pressures but offers exposure to commodity benefits. Upside potential exists with Seeking Alpha's $34.83 price target suggesting over 20% upside, though inflation and monetary policy risks persist. Institutional mixed positioning reflects uncertainty about Australia's economic trajectory amid global commodity fluctuations.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI Australia ETF
EWA tracks the MSCI Australia Index, providing broad exposure to large and mid-cap companies in the Australian equity market. It is structurally dominated by the financial and materials sectors, serving as a key instrument for investors seeking a single-country view of Australia's resource-rich and stable economy.
Read more on EWA →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
